🙌 In Slovakia the first patient was enrolled in the new IVAC 2L Post-Market Clinical Follow-up…
We have a mission!
PulseCath® is focused on developing ground-breaking technologies designed to assist the life sustaining pumping functions of the failing heart.
SEE OUR
Facts & Figures
Registrations
> 50 countries approved registrations
Cases
> 175 shared cases on LinkedIn; > 400 reported cases
> 1.300 iVAC 2L sold
> 35 distributor agreements
Hospitals
> 45 hospitals use iVAC 2L on a regular base; > 9 Centers of Excellence.
Patients
> 600 patients world wide treated by iVAC 2L
Clinical evidence
> 30 publications
Indication
The iVAC 2L is intended for use in patients with impaired left ventricular function which require left ventricular mechanical circulatory support for up to 24 hours
MEET OUR
Medical advisors
Clinical programme supported by leading cardiologists